About the Authors

Marta Garcia-Montojo

mgarciamon.hcsc@salud.madrid.org

Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

María Dominguez-Mozo

Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

Ana Arias-Leal

Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

Ángel Garcia-Martinez

Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

Virginia De las Heras

Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

Ignacio Casanova

Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

Raphaël Faucard

Affiliation Geneuro Innovation, Lyon, France

Nadège Gehin

Affiliation Geneuro Innovation, Lyon, France

Alexandra Madeira

Affiliation Geneuro Innovation, Lyon, France

Rafael Arroyo

Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

François Curtin

Affiliation Geneuro Innovation, Lyon, France

Roberto Alvarez-Lafuente

Affiliation Multiple Sclerosis Unit, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain

Hervé Perron

Affiliation Geneuro Innovation, Lyon, France

Competing Interests

RF, NG, AM, FC and HP are employees of Geneuro and MGM received honoraria from this company for scientific consultancy. The study has been funded in part by Geneuro Innovation, a company developing therapies and diagnostic tools for diseases associated with the expression of human endogenous retroviruses, with a primary focus on the Nervous System diseases and Multiple Sclerosis. There are no patents, further products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: MGM FC HP RAL. Performed the experiments: MGM AAL AGM MDM. Analyzed the data: MGM RAL HP VDH IC RA. Contributed reagents/materials/analysis tools: RF NG AM. Wrote the paper: MGM RAL HP.